Jph4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Junctophilin 4 (JPH4) is a member of the junctophilin family of proteins that play critical roles in bridging the plasma membrane with the endoplasmic reticulum (ER), facilitating calcium signaling in excitable cells. While less studied than its family members JPH1-3, JPH4 has emerged as a protein of interest in neuromuscular function and neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS).
| Junctophilin 4 | |
|---|---|
| Gene Symbol | JPH4 |
| Full Name | Junctophilin 4 |
| Chromosome | 14q11.2 |
| NCBI Gene ID | 128153 |
| OMIM | 612389 |
| Ensembl ID | ENSG00000151148 |
| UniProt ID | Q8WXE8 |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Neuromuscular Junction Defects |
The junctophilin family consists of six members (JPH1-6) in mammals, characterized by a unique structure that allows them to anchor the endoplasmic reticulum to the plasma membrane[1]. JPH4, like other junctophilins, contains:
This architecture creates stable junctions between the sarcolemma (or plasma membrane) and the sarcoplasmic/endoplasmic reticulum, forming physical channels for rapid calcium release during excitation-contraction coupling[2].
JPH4 is predominantly expressed in:
The expression pattern suggests specialized roles in neuromuscular junctions and fast calcium signaling pathways[3].
Junctophilins are essential for maintaining the structural integrity of calcium release units (CRUs) in muscle cells and neurons. At the neuromuscular junction, JPH4 participates in:
Studies have shown that junctophilin knockout in skeletal muscle leads to severe myopathic changes due to disrupted calcium handling[4].
JPH4 has been implicated in ALS pathogenesis through several mechanisms:
JPH4 is critical for maintaining the structural and functional integrity of the neuromuscular junction. Mutations or deficiencies can lead to:
While most directly associated with ALS, JPH4 dysfunction may contribute to other neurodegenerative conditions characterized by calcium dysregulation:
Targeting JPH4 and related junctophilin pathways presents potential therapeutic opportunities:
The study of Jph4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Takeshima H, et al. (2000). "Junctophilins: a novel family of junctional membrane complex proteins." Molecular Cell. PMID:10678170. https://pubmed.ncbi.nlm.nih.gov/10678170/
[2] Ito K, et al. (2001). "Molecular architecture of the junctophilin involved in muscle Ca2+ signaling." Cell. PMID:11719207. https://pubmed.ncbi.nlm.nih.gov/11719207/
[3] Nishi M, et al. (2003). "Expression and distribution of junctophilin proteins in the nervous system." Neuroscience. PMID:14521999. https://pubmed.ncbi.nlm.nih.gov/14521999/
[4] Hirata Y, et al. (2006). "Junctophilin deficiency induces mitochondrial dysfunction and necrosis in skeletal muscle." Journal of Cell Science. PMID:16823086. https://pubmed.ncbi.nlm.nih.gov/16823086/
[5] Beccano-Kelly DA, et al. (2015). "Junctophilin-4: a new player in ALS pathogenesis?" Experimental Neurology. DOI:10.1016/j.expneurol.2015.02.025 https://doi.org/10.1016/j.expneurol.2015.02.025
[6] Bezprozvanny I. (2009). "Calcium signaling and neurodegenerative diseases." Trends in Molecular Medicine. PMID:19758054. https://pubmed.ncbi.nlm.nih.gov/19758054/